ProSomnus® Receives Additional U.S. Utility Patent Covering Iterative Titration Technology for Company’s Novel Precision Sleep Apnea Medical Devices

Rhea-AI Summary

ProSomnus, Inc. (NASDAQ: OSA) announced that the U.S. Patent and Trademark Office granted U.S. patent serial number 11,617,677 on April 4, 2023. This patent adds to ProSomnus's impressive portfolio, now totaling 17 issued patents covering its iterative titration technology for Precision Oral Appliance Therapy (OAT) devices. This technology enhances device performance by improving airflow and patient comfort. ProSomnus's FDA-cleared devices offer a competitive alternative to traditional CPAP machines, demonstrating strong patient compliance and efficacy. Over 200,000 devices have been delivered, underlining their demand in the OSA treatment market.

Positive

• U.S. Patent 11,617,677 strengthens ProSomnus's intellectual property portfolio.
• ProSomnus's devices show excellent efficacy and robust patient compliance in clinical studies.
• Over 200,000 devices delivered, indicating strong market demand for Precision OAT.

Negative

• None.

PLEASANTON, Calif., April 05, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today announced that the U.S. Patent and Trademark Office (USPTO) issued U.S. patent serial number (USPN) 11,617,677 on April 4, 2023, an addition to a portfolio of several issued U.S. patents covering the Company’s iterative titration technology featured in its FDA-cleared and patient-preferred Precision Oral Appliance Therapy (OAT) devices. ProSomnus’s intellectual property portfolio now includes 17 issued patents in the United States and other countries, encompassing more than 100 claims, in addition to trademarks, trade secrets and other patent applications in process.

“Our patented iterative titration technology is a cornerstone of our differentiation," said Len Liptak, Co-Founder and Chief Executive Officer of ProSomnus. "Iterative titration enables the mechanism of action for our precision medicine approach to treating Obstructive Sleep Apnea. By eliminating the components used by dental product style devices, iterative titration allows ProSomnus devices to be smaller, stronger and made from Medical Grade Class VI materials, too. This continuation patent strengthens the Company’s deep intellectual property portfolio as we continue meeting a growing demand for our patient-preferred Precision Oral Appliance Therapy.”

ProSomnus’s FDA-cleared, Precision OAT devices are a practical alternative to legacy oral devices and CPAP machines. In clinical studies, ProSomnus devices have demonstrated excellent efficacy and robust patient compliance relative to other treatment options. They reposition and stabilize the jaw during sleep, improving airflow through a patient's pharyngeal space. ProSomnus Precision OAT devices consist of maxillary and mandibular aligners that are precision-manufactured with twin-mated posts, and are digitally milled to be patient-specific. Prescribed advancements can be achieved by removing the current upper- or lower-device arch and inserting the next arch in the mandibular advancement series.

About ProSomnus
ProSomnus (NASDAQ: OSA) precision intraoral medical devices offer effective, economical, and patient-preferred treatment for patients suffering from Obstructive Sleep Apnea (OSA). ProSomnus is the first manufacturer of mass-customized Precision Oral Appliance Therapy (OAT) devices to treat OSA, which affects over 74 million people in North America and is associated with serious comorbidities, including heart failure, stroke, hypertension, morbid obesity, and type 2 diabetes. ProSomnus’s patented, FDA-cleared devices are a less invasive and more comfortable alternative to Continuous Positive Airway Pressure (CPAP) therapy, and lead to effective and patient-preferred outcomes. A growing body of research, including studies published by the Journal of Clinical Sleep Medicine and Military Medicine, suggests ProSomnus’s Precision OAT devices are an effective treatment for mild to moderate OSA. Additional clinical research has shown that ProSomnus’s Precision OAT devices mitigate many of the side effects associated with alternative treatments and improve economics for payers and providers. With more than 200,000 devices delivered, ProSomnus’s devices are the most prescribed Precision OAT in the U.S. ProSomnus’s FDA-cleared devices are authorized by the Department of Defense and the U.S. Army, and are often covered by medical insurance, Medicare, and social health programs in key international markets. To learn more, visit www.ProSomnus.com.

Investor Contact
Mike Cavanaugh
ICR Westwicke
Phone: +1.617.877.9641
Email: Mike.Cavanaugh@westwicke.com

Media Contact
Elizabeth Coleman
ICR Westwicke
Phone: +1.203.682.4783
Email: Elizabeth.Coleman@westwicke.com

 

FAQ

What is the significance of U.S. patent 11,617,677 for ProSomnus (OSA)?

The patent strengthens ProSomnus's intellectual property portfolio by protecting its innovative iterative titration technology essential for its Precision Oral Appliance Therapy devices.

How do ProSomnus devices compare to traditional CPAP machines?

ProSomnus devices offer a less invasive, more comfortable treatment alternative with demonstrated strong patient compliance and efficacy, making them preferred over CPAP machines.

What is the market demand for ProSomnus's OSA treatment devices?

ProSomnus has delivered over 200,000 devices, indicating a growing demand for their Precision Oral Appliance Therapy in the Obstructive Sleep Apnea market.

When was the patent for ProSomnus's technology issued?

U.S. patent serial number 11,617,677 was issued on April 4, 2023.

What are the benefits of ProSomnus's Precision Oral Appliance Therapy?

The therapy improves airflow and patient comfort while mitigating side effects associated with alternative treatments.